AstraZeneca wins approval in China for early-stage lung cancer treatment Tagrisso
AstraZeneca PLC (LON:AZN) said its prescription medicine Tagrisso (osimertinib) was approved in China for the adjuvant treatment of patients with early-stage lung cancer.
Read More